样式: 排序: IF: - GO 导出 标记为已读
-
Mobilization and Hematopoietic Stem Cell Collection in Poor Mobilizing Patients with Lymphoma: Final Results of the German OPTIMOB Study. Transfus. Med. Hemother. (IF 2.2) Pub Date : 2023-09-21 Katharina Kriegsmann,Max Bittrich,Sandra Sauer,Carola Tietze-Stolley,Kamran Movassaghi,Matthias Grube,Vladan Vucinic,Daniela Wehler,Andreas Burchert,Martin Schmidt-Hieber,Andreas Rank,Heinz A Dürk,Bernd Metzner,Christoph Kimmich,Marcus Hentrich,Christian Kunz,Frank Hartmann,Cyrus Khandanpour,Maike de Wit,Udo Holtick,Michael Kiehl,Andrea Stoltefuß,Alexander Kiani,Ralph Naumann,Christian W Scholz,Hans-Joachim
Introduction Successful mobilization and collection of peripheral hematopoietic stem cells (HSCs) are necessary for lymphoma patients eligible for myeloablative chemotherapy with subsequent autologous stem cell transplantation (ASCT). Albeit G-CSF alone or combined with chemotherapy is well-established methods for HSC mobilization, up to 40% of the patients fail to mobilize (poor mobilizer, PM). Plerixafor
-
Flow Cytometric Characterization of Hematopoietic Stem and Progenitor Cell Subpopulations in Autologous Peripheral Blood Stem Cell Preparations after Cryopreservation. Transfus. Med. Hemother. (IF 2.2) Pub Date : 2023-09-15 Anabel Heuer,Svea Löwhagen,Stefanie Uhlig,Svetlana Hetjens,Sylvia Büttner,Britta Pflästerer,Anke Diehlmann,Stefan Klein,Harald Klüter,Karen Bieback,Patrick Wuchter
Introduction Autologous stem cell transplantation is a successful routine procedure with only a small number of non-engraftment cases, although the time to hematopoietic recovery may vary considerably across patients. While CD34 has been the decisive marker for enumerating hematopoietic stem and progenitor cells (HSPCs) for more than 30 years, the impact of CD34-positive cellular subpopulations in
-
Stem Cell Mobilization, Collection, and Processing. Transfus. Med. Hemother. (IF 2.2) Pub Date : 2023-09-05 Katharina Kriegsmann,Patrick Wuchter
-
Mobilization Strategies in Myeloma Patients Intended for Autologous Hematopoietic Cell Transplantation. Transfus. Med. Hemother. (IF 2.2) Pub Date : 2023-08-24 Esa Jantunen,Anu Partanen,Antti Turunen,Ville Varmavuo,Raija Silvennoinen
Background Multiple myeloma is currently the leading indication for autologous hematopoietic cell transplantation (AHCT). A prerequisite for AHCT is mobilization and collection of adequate blood graft to support high-dose therapy. Current mobilization strategies include granulocyte colony-stimulating factor (G-CSF) alone or in combination with chemotherapy most commonly cyclophosphamide (CY). More
-
CD34+ Cell Mobilization, Autograft Cellular Composition and Outcome in Mantle Cell Lymphoma Patients. Transfus. Med. Hemother. (IF 2.2) Pub Date : 2023-08-23 Antti Samuli Turunen,Outi Kuittinen,Hanne Kuitunen,Kaija Vasala,Karri Penttilä,Minna Harmanen,Leena Keskinen,Pentti Mäntymaa,Jukka Pelkonen,Ville Varmavuo,Esa Jantunen,Anu Partanen
Backgound Autologous stem cell transplantation (ASCT) is a standard treatment in transplant-eligible mantle cell lymphoma (MCL) patients after first-line chemoimmunotherapy. Study Design and Methods This prospective multicenter study evaluated the impact of CD34+ cell mobilization and graft cellular composition analyzed by flow cytometry on hematologic recovery and outcome in 42 MCL patients. Results
-
Predicting Successful Hematopoietic Stem Cell Collection in Healthy Allogeneic Donors. Transfus. Med. Hemother. (IF 2.2) Pub Date : 2023-06-30 Sabine Kayser,Richard F Schlenk,Marcus Steiner,Harald Klüter,Patrick Wuchter
Introduction Collection of peripheral blood stem cells (PBSCs) from healthy donors is a well-established process. We aimed to identify factors predictive of successful CD34+ PBSC collection and established a formula capable of predicting CD34+ cell yield. Methods We retrospectively evaluated 588 healthy adult donors (median age 29 years, range 18-69 years) at our institution from 2017 to 2022. The
-
Impact of Clinical Parameters and Induction Regimens on Peripheral Blood Stem-Cell Mobilization and Collection in Multiple Myeloma Patients. Transfus. Med. Hemother. (IF 2.2) Pub Date : 2023-06-05 Sandra Sauer,Lennart Hieke,Juliane Brandt,Carsten Müller-Tidow,Anita Schmitt,Joseph Kauer,Katharina Kriegsmann
Introduction High-dose chemotherapy (HDCT) followed by autologous blood stem-cell transplantation (ABSCT) remains the standard consolidation therapy for newly diagnosed eligible multiple myeloma (MM) patients. As a prerequisite, peripheral blood stem cells (PBSCs) must be mobilized and collected by leukapheresis (LP). Many factors can hamper PBSC mobilization/collection. Here, we provide a comprehensive
-
Big Data in Transfusion Medicine and Artificial Intelligence Analysis for Red Blood Cell Quality Control. Transfus. Med. Hemother. (IF 2.2) Pub Date : 2023-05-25 Marcelle G M Lopes,Steffen M Recktenwald,Greta Simionato,Hermann Eichler,Christian Wagner,Stephan Quint,Lars Kaestner
Background "Artificial intelligence" and "big data" increasingly take the step from just being interesting concepts to being relevant or even part of our lives. This general statement holds also true for transfusion medicine. Besides all advancements in transfusion medicine, there is not yet an established red blood cell quality measure, which is generally applied. Summary We highlight the usefulness
-
Omics and Machine Learning in Transfusion Medicine. Transfus. Med. Hemother. (IF 2.2) Pub Date : 2023-05-25 Angelo D'Alessandro,Peter Bugert
-
Omics Technologies in Veterinary Medicine: Literature Review and Perspectives in Transfusion Medicine. Transfus. Med. Hemother. (IF 2.2) Pub Date : 2023-05-25 Arianna Miglio,Valentina Cremonini,Leonardo Leonardi,Elisabetta Manuali,Paola Coliolo,Olimpia Barbato,Cecilia Dall'Aglio,Maria Teresa Antognoni
Background Omics technologies represent a new analytical approach that allows a full cellular readout through the simultaneous analysis of thousands of molecules. The application of such technologies represents a flourishing field of research in human medicine, especially in transfusion medicine, while their application in veterinary medicine still needs to be developed. Summary Omics technologies
-
Rapid Identification of Seven Common ABO Alleles by Two-Dimensional Polymerase Chain Reaction Technology Transfus. Med. Hemother. (IF 2.2) Pub Date : 2023-04-24 Jin Chen, Yuxia Zhan, Jun Zhang, Yang Yu, Shuang Yao, Guanghua Luo
Introduction: The molecular biology detection technology of the human ABO blood group system makes up for the limitations in many aspects compared with conventional serological typing technology. This study aimed to establish a new method to identify seven common ABO alleles (ABO*A1.01, ABO*A1.02, ABO*A2.01, ABO*B.01, ABO*O.01.01, ABO*O.01.02, and ABO*O.02.01) by two-dimensional polymerase chain reaction
-
Effect of Plasma Unit Weight and Donor Sex on Post-Donation Citrate Level: An Experimental Study on Plasmapheresis Donors Transfus. Med. Hemother. (IF 2.2) Pub Date : 2023-04-20 Chiara Marraccini, Davide Schiroli, Pamela Mancuso, Giuseppe Molinari, Agnese Razzoli, Gaia Gavioli, Tommaso Fasano, Roberto Baricchi, Paolo Giorgi Rossi, Lucia Merolle
Introduction: Plasmapheresis donation is considered safe and well tolerated, although long-term effects need to be clarified. The volumes of anticoagulant (ACD-A) used are variable and depend primarily on hematocrit (HCT), total blood processed, amount of plasma collected, and donor characteristics. To elucidate the effect of the plasma unit weight setting on plasmapheresis efficiency and ACD-A distribution
-
Defining Current Patterns of Blood Product Use during Intensive Induction Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia Patients Transfus. Med. Hemother. (IF 2.2) Pub Date : 2023-04-13 Liron Miller, Mor Freed-Freundlich, Avichai Shimoni, Tamer Hellou, Abraham Avigdor, Mudi Misgav, Jonathan Canaani
Introduction: Blood product transfusion retains a critical role in the supportive care of patients with acute myeloid leukemia (AML). Whereas previous studies have shown increased transfusion dependency to portend inferior outcome, predictive factors of an increased transfusion burden and the prognostic impact of transfusion support have not been assessed recently. Methods/Patients: We performed a
-
Too Early to Abandon Convalescent Plasma for Supportive Treatment of COVID-19 Transfus. Med. Hemother. (IF 2.2) Pub Date : 2023-04-03 Rainer Seitz, Lutz Gürtler, Ute Vahlensieck, Anneliese Hilger, Wolfgang Schramm
The authors of a systematic review and meta-analysis conclude that the benefit of convalescent plasma (CP) in the treatment of COVID-19 is limited. Among other systematic reviews, only one found an indication of benefit of CP. However, a meta-analysis needs a focused and meaningful clinical question and should include studies which are designed to test a reasonable hypothesis. Clinical trials to support
-
Association of Circulating Procoagulant Microvesicles with Painful Vaso-Occlusive Crisis in Sickle Cell Disease Transfus. Med. Hemother. (IF 2.2) Pub Date : 2023-03-30 Akbar Hashemi Tayer, Reza Ranjbaran, Maryam Kamravan, Mojdeh Abbasi, Reyhaneh Zareian
Introduction: Thrombotic complication is one of the features of sickle cell disease (SCD), characterized by appearance of phosphatidylserine on the outer membrane of sickle-shaped red blood cells and most abundantly on membrane protrusions called microvesicles (MVs). However, the exact mechanism by which MVs may enhance coagulant activity in SCD patients has not been fully addressed. The aim of this
-
Autologous Stem Cell Collection after Daratumumab, Bortezomib, Thalidomide, and Dexamethasone versus Bortezomib, Cyclophosphamide, and Dexamethasone in Newly Diagnosed Multiple Myeloma Transfus. Med. Hemother. (IF 2.2) Pub Date : 2023-03-24
Introduction: In transplant-eligible, newly diagnosed multiple myeloma (NDMM) patients, autologous peripheral blood stem cell (PBSC) collection is usually pursued after induction therapy. While induction regimens are constantly refined regarding response, their impact on PBSC collection is not fully studied. The inclusion of the anti-CD38 antibody daratumumab into induction therapy significantly improved
-
-
Principles of Therapeutic Apheresis in Neurological Disease Transfus. Med. Hemother. (IF 2.2) Pub Date : 2023-03-14
Background: Therapeutic plasma exchange (TPE) is a well-known apheresis technology since many years and is available worldwide. Myasthenia gravis is one of the first neurological diseases successfully treated with TPE. TPE is also frequently applied in acute inflammatory demyelinating polyradiculoneuropathy (Guillain-Barré syndrome). Both neurological disorders are immunologically mediated and might
-
Circulating Iron in Patients with Sickle Cell Disease Mediates the Release of Neutrophil Extracellular Traps Transfus. Med. Hemother. (IF 2.2) Pub Date : 2023-03-15 Kristof Van Avondt, Marein Schimmel, Ingrid Bulder, Gerard van Mierlo, Erfan Nur, Robin van Bruggen, Bart J. Biemond, Brenda M. Luken, Sacha Zeerleder
Introduction: Neutrophils promote chronic inflammation and release neutrophil extracellular traps (NETs) that can drive inflammatory responses. Inflammation influences progression of sickle cell disease (SCD), and a role for NETs has been suggested in the onset of vaso-occlusive crisis (VOC). We aimed to identify factors in the circulation of these patients that provoke NET release, with a focus on
-
Predicting Individual Patient Platelet Demand in a Large Tertiary Care Hospital Using Machine Learning Transfus. Med. Hemother. (IF 2.2) Pub Date : 2023-03-09
Introduction: An increasing shortage of donor blood is expected, considering the demographic change in Germany. Due to the short shelf life and varying daily fluctuations in consumption, the storage of platelet concentrates (PCs) becomes challenging. This emphasizes the need for reliable prediction of needed PCs for the blood bank inventories. Therefore, the objective of this study was to evaluate
-
Principles of Therapeutic Apheresis in Neurological Disease Transfus. Med. Hemother. (IF 2.2) Pub Date : 2023-03-14
Background: Therapeutic plasma exchange (TPE) is a well-known apheresis technology since many years and is available worldwide. Myasthenia gravis is one of the first neurological diseases successfully treated with TPE. TPE is also frequently applied in acute inflammatory demyelinating polyradiculoneuropathy (Guillain-Barré syndrome). Both neurological disorders are immunologically mediated and might
-
Predicting Individual Patient Platelet Demand in a Large Tertiary Care Hospital Using Machine Learning Transfus. Med. Hemother. (IF 2.2) Pub Date : 2023-03-09 Merlin Engelke, Christian Martin Brieske, Vicky Parmar, Nils Flaschel, Anisa Kureishi, Rene Hosch, Sven Koitka, Cynthia Sabrina Schmidt, Peter A. Horn, Felix Nensa
Introduction: An increasing shortage of donor blood is expected, considering the demographic change in Germany. Due to the short shelf life and varying daily fluctuations in consumption, the storage of platelet concentrates (PCs) becomes challenging. This emphasizes the need for reliable prediction of needed PCs for the blood bank inventories. Therefore, the objective of this study was to evaluate
-
Red Blood Cell Omics and Machine Learning in Transfusion Medicine: Singularity Is Near Transfus. Med. Hemother. (IF 2.2) Pub Date : 2023-03-08 Angelo D’Alessandro
Background: Blood transfusion is a life-saving intervention for millions of recipients worldwide. Over the last 15 years, the advent of high-throughput, affordable omics technologies – including genomics, proteomics, lipidomics, and metabolomics – has allowed transfusion medicine to revisit the biology of blood donors, stored blood products, and transfusion recipients. Summary: Omics approaches have
-
Red Blood Cell Omics and Machine Learning in Transfusion Medicine: Singularity Is Near Transfus. Med. Hemother. (IF 2.2) Pub Date : 2023-03-08
Background: Blood transfusion is a life-saving intervention for millions of recipients worldwide. Over the last 15 years, the advent of high-throughput, affordable omics technologies – including genomics, proteomics, lipidomics, and metabolomics – has allowed transfusion medicine to revisit the biology of blood donors, stored blood products, and transfusion recipients. Summary: Omics approaches have
-
Diagnosis of Bone Marrow Necrosis following Severe Vaso-Occlusive Crisis in Patient with Compound Heterozygous Sickle Cell Disease Transfus. Med. Hemother. (IF 2.2) Pub Date : 2023-03-07 Daniel N. Marco, Joan Cid, Marta Garrote, Albert Cortés-Bullich, Ferran Seguí, Miquel Lozano
Introduction: Bone marrow necrosis is a rare entity that can develop in context of a sickle cell disease vaso-occlusive crisis. Its physiopathology is related to an endothelial dysfunction taking place in bone marrow microvasculature. Case Presentation: A 30-year-old patient with history of compound heterozygous sickle cell disease was admitted following SARS-CoV-2 infection with fever and diarrhea
-
How to Ensure Blood Supply and Blood Safety in the Future Transfus. Med. Hemother. (IF 2.2) Pub Date : 2023-03-07
Transfus Med Hemother
-
Diagnosis of Bone Marrow Necrosis following Severe Vaso-Occlusive Crisis in Patient with Compound Heterozygous Sickle Cell Disease Transfus. Med. Hemother. (IF 2.2) Pub Date : 2023-03-07
Introduction: Bone marrow necrosis is a rare entity that can develop in context of a sickle cell disease vaso-occlusive crisis. Its physiopathology is related to an endothelial dysfunction taking place in bone marrow microvasculature. Case Presentation: A 30-year-old patient with history of compound heterozygous sickle cell disease was admitted following SARS-CoV-2 infection with fever and diarrhea
-
How to Ensure Blood Supply and Blood Safety in the Future Transfus. Med. Hemother. (IF 2.2) Pub Date : 2023-03-07
Transfus Med Hemother
-
New Trends in Hemapheresis Transfus. Med. Hemother. (IF 2.2) Pub Date : 2023-03-02 Nina Worel, Andreas Buser, Sixten Körper
Transfus Med Hemother
-
New Trends in Hemapheresis Transfus. Med. Hemother. (IF 2.2) Pub Date : 2023-03-02
Transfus Med Hemother
-
Success Rate and Long-Term Effects of Embolization of Pelvic Arteries for the Treatment of Postpartum Hemorrhage Transfus. Med. Hemother. (IF 2.2) Pub Date : 2023-02-21 Kapfhammer Elisabeth, Pfammatter Thomas, Brun Romana, Zimmermann Roland, Haslinger Christian
Introduction: Postpartum hemorrhage (PPH) is the leading cause of peripartal maternal mortality and accounts for 25% of all maternal deaths worldwide. The most common reasons of PPH are uterine atony, retained placenta, or placenta accreta spectrum. Treatment of PPH depends on the etiology and corresponds to a stepwise approach, which follows the German, Austrian and Swiss guideline for the diagnosis
-
Success Rate and Long-Term Effects of Embolization of Pelvic Arteries for the Treatment of Postpartum Hemorrhage Transfus. Med. Hemother. (IF 2.2) Pub Date : 2023-02-21
Introduction: Postpartum hemorrhage (PPH) is the leading cause of peripartal maternal mortality and accounts for 25% of all maternal deaths worldwide. The most common reasons of PPH are uterine atony, retained placenta, or placenta accreta spectrum. Treatment of PPH depends on the etiology and corresponds to a stepwise approach, which follows the German, Austrian and Swiss guideline for the diagnosis
-
Effects of Different Hemoglobin Levels on Near-Infrared Spectroscopy-Derived Cerebral Oxygen Saturation in Elderly Patients Undergoing Noncardiac Surgery Transfus. Med. Hemother. (IF 2.2) Pub Date : 2023-02-08
Background: Near-infrared spectroscopy (NIRS) is a commonly used technique to evaluate tissue oxygenation and prevent harmful cerebral desaturation in the perioperative setting. The aims of the present study were to assess whether surgery-related anemia can be detected via NIRS of cerebral oxygen saturation and to investigate the effects of different perioperative transfusion strategies on cerebral
-
Effects of Different Hemoglobin Levels on Near-Infrared Spectroscopy-Derived Cerebral Oxygen Saturation in Elderly Patients Undergoing Noncardiac Surgery Transfus. Med. Hemother. (IF 2.2) Pub Date : 2023-02-08
Background: Near-infrared spectroscopy (NIRS) is a commonly used technique to evaluate tissue oxygenation and prevent harmful cerebral desaturation in the perioperative setting. The aims of the present study were to assess whether surgery-related anemia can be detected via NIRS of cerebral oxygen saturation and to investigate the effects of different perioperative transfusion strategies on cerebral
-
PharmaNews Transfus. Med. Hemother. (IF 2.2) Pub Date : 2023-02-02
Transfus Med Hemother 2023;50:71–74
-
Molecular Screening of Blood Donors for Babesia in Tyrol, Austria Transfus. Med. Hemother. (IF 2.2) Pub Date : 2023-02-02 Evan M. Bloch, Anita Siller, Laura Tonnetti, Steven J. Drews, Bryan R. Spencer, Doris Hedges, Tessa Mergenthal, Marijke Weber-Schehl, Manfred Astl, Eshan U. Patel, Manfred Gaber, Harald Schennach, for the ISBT TTID Working Party Parasite subgroup
Introduction: Babesia is a tick-borne intraerythrocytic parasite that is globally ubiquitous, yet understudied. Several species of Babesia have been shown to be transfusion-transmissible. Babesia has been reported in blood donors, animals, and ticks in the Tyrol (Western Austria), and regional cases of human babesiosis have been described. We sought to characterize the risk of Babesia to the local
-
PharmaNews Transfus. Med. Hemother. (IF 2.2) Pub Date : 2023-02-02
Transfus Med Hemother 2023;50:71–74
-
Molecular Screening of Blood Donors for Babesia in Tyrol, Austria Transfus. Med. Hemother. (IF 2.2) Pub Date : 2023-02-02
Introduction: Babesia is a tick-borne intraerythrocytic parasite that is globally ubiquitous, yet understudied. Several species of Babesia have been shown to be transfusion-transmissible. Babesia has been reported in blood donors, animals, and ticks in the Tyrol (Western Austria), and regional cases of human babesiosis have been described. We sought to characterize the risk of Babesia to the local
-
Non-Invasive Zinc Protoporphyrin Screening Offers Opportunities for Secondary Prevention of Iron Deficiency in Blood Donors Transfus. Med. Hemother. (IF 2.2) Pub Date : 2023-01-24 Anne Schliemann, Christian Homann, Georg Hennig, Alexander Lang, Lesca Miriam Holdt, Michael Vogeser, Ronald Sroka, Herbert Stepp, Franz Weinauer, Ernst-Markus Quenzel
Background: Frequent blood donors are at high risk of developing iron deficiency. Currently, there is no potent screening during blood donation to detect iron deficient erythropoiesis (IDE) before anemia develops and deferral from donation is inevitable. Study Design and Methods: In addition to capillary and venous hemoglobin, the iron status of 99 frequent blood donors was assessed by various venous
-
Challenges for Plasma-Derived Medicinal Products Transfus. Med. Hemother. (IF 2.2) Pub Date : 2023-01-18 Paul F.W. Strengers
Background: Plasma-derived medicinal products (PDMPs) are medicinal products derived from human plasma, and a number of PDMPs are listed on the WHO Model List of Essential Medicines. These and other PDMPs are crucial for the prophylaxis and treatment of patients with immune deficiencies, autoimmune and inflammatory diseases, bleeding disorders, and a variety of congenital deficiency disorders. The
-
Safety and Feasibility of Immunoadsorption with Heparin Anticoagulation in Preparation of ABO-Incompatible Kidney Transplantation: A Retrospective Single-Center Study Transfus. Med. Hemother. (IF 2.2) Pub Date : 2023-01-18 Till Junker, Thomas Volken, Gregor Stehle, Beatrice Drexler, Laura Infanti, Andreas Buser, Jakob Passweg, Stefan Schaub, Michael Dickenmann, Jörg Halter, Andreas Holbro
Introduction: Immunoadsorption (IA) of isohemagglutinins is an often-crucial procedure in preparation of major ABO blood group-incompatible living donor kidney transplantation (ABOi LDKT). Standard citrate-based anticoagulation during the procedure has potential disadvantages for distinct patient groups. In this study, we report our experience with an alternative anticoagulation scheme using heparin
-
Monitoring Blood Supply in Germany: A Regulatory Perspective Transfus. Med. Hemother. (IF 2.2) Pub Date : 2023-01-18 Sarah Anna Fiedler, Olaf Henseler, Marcus Hoffelner, Manfred Doll, Gabriele Hutschenreuter, Jochen Hoch, Franz Weinauer, Andreas Humpe, Markus Benedikt Funk, Anneliese Hilger
Background and Objectives: A sufficient supply of safe, high-quality blood components for transfusion is essential to the healthcare system in Germany. The requirements for the current reporting system are laid down in the German Transfusion Act. The present work elaborates on the advantages and limitations of the current reporting system and investigates the feasibility of a pilot project that collects
-
The Impact of Prepartum Platelet Count on Postpartum Blood Loss and Its Association with Coagulation Factor XIII Activity Transfus. Med. Hemother. (IF 2.2) Pub Date : 2023-01-18 Romana Brun, Torsten Hothorn, Eva Eigenmann, Marie Louise Frevert, Roland Zimmermann, Wolfgang Korte, Christian Haslinger
Background: Postpartum hemorrhage is a leading cause of maternal morbidity and mortality worldwide. Contradictory information exists regarding the relevance of prepartum platelet count on postpartum hemorrhage. We have shown prepartum coagulation factor XIII to be associated with postpartum blood loss; however, little is known about the association of platelet count with factor XIII activity. Our objectives
-
Evaluation of Single Nucleotide Variants in Intron 1 of the ABO Gene as Diagnostic Markers for the A1 Blood Group Transfus. Med. Hemother. (IF 2.2) Pub Date : 2023-01-18
Introduction: The molecular diagnosis of the A1 blood group is based on the exclusion of ABO gene variants causing blood groups A2, B, or O. A specific genetic marker for the A1 blood group is still missing. Recently, long-read ABO sequencing revealed four sequence variations in intron 1 as promising markers for the ABO*A1 allele. Here, we evaluated the diagnostic values of the 4 variants in blood
-
Identification of Lutheran Blood Groups and Genetic Variants within KLF1 among Thai Blood Donors Transfus. Med. Hemother. (IF 2.2) Pub Date : 2023-01-18 Kamphon Intharanut, Piyathida Khumsuk, Oytip Nathalang
Background: Lua and Lub are inherited as codominant allelic characters resulting from a single nucleotide variant (SNV) of the basal cell adhesion molecule (BCAM) gene. Red cells of the dominantly inherited suppressor of the Lutheran antigens In(Lu) phenotypically appear as Lu(a−b–) by the haemagglutination test. In(Lu) resulted from heterozygosity for mutations within the erythroid-specific Krüppel-like
-
Postpartum Hemorrhage: A Rising Problem Requiring to Think Out of the Box Transfus. Med. Hemother. (IF 2.2) Pub Date : 2023-01-16 Christian Haslinger, Wolfgang Korte
Transfus Med Hemother
-
Patient Blood Management in Pregnancy Transfus. Med. Hemother. (IF 2.2) Pub Date : 2023-01-06 Alexander Kaserer, Clara Castellucci, David Henckert, Christian Breymann, Donat R. Spahn
Background: Patient blood management (PBM) is a multidisciplinary and patient-centered treatment approach, comprising the detection and treatment of anemia, the minimization of blood loss, and the rational use of allogeneic transfusions. Pregnancy, delivery, and the puerperium are associated with increased rates of iron deficiency and anemia, which correlates with worse maternal and fetal outcomes
-
Analysis of Transfusion-Transmitted Bacterial Infections according to German Hemovigilance Data (2011–2020) Transfus. Med. Hemother. (IF 2.2) Pub Date : 2022-12-29 Stefano Orru’, Doris Oberle, Margarethe Heiden, Susanne Müller, Oleg Krut, Markus Benedikt Funk
Introduction: Following the first assessment of the effects of safety measures taken against transfusion-transmitted bacterial infections (TTBI), the Paul-Ehrlich-Institut (PEI) decided to newly analyze risk minimization measures (RMM) using German hemovigilance data from 2011 to 2020, focusing on blood components, recipients, and bacterial strains. Materials and Methods: The PEI assessed the imputability
-
Platelet-Rich Fibrin in Oral Surgery and Implantology: A Narrative Review Transfus. Med. Hemother. (IF 2.2) Pub Date : 2022-12-22 Katharina Zwittnig, Khaled Mukaddam, Daniel Vegh, Valentin Herber, Norbert Jakse, Peter Schlenke, Tomislav Ante Zrnc, Michael Payer
Background: The application of blood concentrates has gained popularity in dentistry in recent years. Platelet-rich fibrin (PRF) has been discussed frequently due to a high content of growth factors and the option of chair-side manufacturing in a simple centrifugation process. PRF is free from adjuvants and inexpensive to produce. The number of studies reporting beneficial effects of PRF in various
-
Get Off on the Right Foot: How to Plan an Efficient Leukocytapheresis to Collect T Cells for CAR T-Cell Manufacturing Transfus. Med. Hemother. (IF 2.2) Pub Date : 2022-12-22 Juan A. Piñeyroa, Joan Cid, Miquel Lozano
Background: The major drug regulatory agencies have approved chimeric antigen receptor (CAR) T cells for the treatment of some B-cell lymphoproliferative diseases. Their use is expanding, and new indications will be approved. Efficient mononuclear cell collection by apheresis providing enough T cells is a critical step in further CAR T-cell manufacturing process. It is important that apheresis units
-
Strengthening Blood Regulatory Systems to Tackle Africa’s Unmet Needs for Blood and Blood Products Transfus. Med. Hemother. (IF 2.2) Pub Date : 2022-12-22 Washington T. Samukange, Chancelar Kafere, Kristina Heinrich, George T. Sabblah, Mwewa M. Siame, Libert Chirinda, Jens Reinhardt, Anneliese Hilger
Background: Assuring the quality and safety of blood and blood components is an essential element of health care in all countries and requires government commitment and legal frameworks. Ineffective regulation of blood and blood components has far-reaching consequences that are not limited to the affected countries but also have extensive global implications. Summary: In this review, we summarize the
-
Indications for the Use of Therapeutic Plasma in Adult Patients Transfus. Med. Hemother. (IF 2.2) Pub Date : 2022-12-14 Christian von Heymann, Heiko Lier, Christoph Rosenthal, Lutz Kaufner
Background: Different preparations for therapeutic plasma are available on the market. The German hemotherapy guideline has been completely updated in 2020 and, for this purpose, has reviewed the evidence for the most frequent clinical indications for the use of therapeutic plasma in adult patients. Summary: The German hemotherapy guideline has reviewed the evidence for the following indications for
-
Detection of Acute Traumatic Coagulopathy by Viscoelastic Haemostatic Assays Compared to Standard Laboratory Tests: A Systematic Review Transfus. Med. Hemother. (IF 2.2) Pub Date : 2022-12-12 Ellen K. Forster, Simon Hendel, Biswadev Mitra
Introduction: The aim of this systematic review was to investigate whether viscoelastic haemostatic assays (VHAs) offer comparative diagnostic ability of acute traumatic coagulopathy (ATC) compared to the standard laboratory coagulation tests (SLCT). ATC is a complication of major trauma characterized by dysfunctional blood clotting, leading to an increased bleeding risk. Additionally, we aimed to
-
Pilot Study to Gain First Indications for the Impact of a 3-Month’s Oral Intake of a Sucrosomial Iron Supplement on Hemoglobin in Iron-Deficient Blood Donors Transfus. Med. Hemother. (IF 2.2) Pub Date : 2022-12-06 Patrick Paul Torreiter, Camilla Drexler-Helmberg, Wolfgang Schimetta, Petra Krakowitzky, Wolfgang Helmberg, Peter Schlenke
Introduction: Regular whole blood donors often suffer from iron deficiency (ID) or iron deficiency anemia due to the loss of 200–300 mg of iron with each donation. Hemoglobin (Hb) as donor eligibility criterion reflects iron stores only poorly. ID in blood donors is typically prevented or treated with orally administered ferrous salts, which frequently cause gastrointestinal side effects. A high daily
-
-
-
Acknowledgement to Reviewers Transfus. Med. Hemother. (IF 2.2) Pub Date : 2022-12-02
Transfus Med Hemother 2022;49:408–409
-
Contents Vol. 49, 2022 Transfus. Med. Hemother. (IF 2.2) Pub Date : 2022-12-02
Transfus Med Hemother 2022;49:I–VI
-
Regulatory Measures to Improve the Safety of CAR-T-Cell Treatment Transfus. Med. Hemother. (IF 2.2) Pub Date : 2022-11-29 Philipp Berg, Sonja Schönefeld, Gabriele Ruppert-Seipp, Markus B. Funk
Introduction: Regulatory activities aim to facilitate the safe use of novel therapeutics such as genetically engineered chimeric antigen receptor (CAR)-T cells. Toxicities associated with CAR-T-cell therapies have led to modified safety management guidance in clinical trials and the implementation of post-marketing requirements. The aim of this study was to estimate the effect of individual risk-minimizing
-
Immunoglobulin Class Profiles of ABO Antibodies in Saliva and Serum of Healthy Individuals Transfus. Med. Hemother. (IF 2.2) Pub Date : 2022-11-29 Marlies Schönbacher, Chiara Banfi, Andrea Berghold, Eva Maria Matzhold, Thomas Wagner, Wolfgang R. Mayr, Günther F. Körmöczi
Introduction: The coronavirus disease (COVID-19) pandemic gave rise to studies investigating the association of ABO blood group with COVID-19 susceptibility. It is hypothesized that ABO antibodies might play a role in neutralizing SARS-CoV-2. However, ABO antibodies were exclusively analyzed in blood samples. Investigation of ABO antibodies in saliva, an easy-to-obtain surrogate for respiratory secretions